Health Condition 1: K859- Acute pancreatitis, unspecified
Conditions
Interventions
Intervention1: Rifaximin: Rifaximin, 400 mg thrice daily, enteral route, Tablet/syrup, maximum upto 28 days.
Control Intervention1: standard of care: standard of care
Sponsors
Anurag Kumar Tiwari
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years to 65 years presenting with their first attack of acute pancreatitis within first 14 days from onset of pancreatitis and have systemic inflammatory response syndrome (SIRS) at presentation will be included in the study.
Exclusion criteria
Exclusion criteria: Patients with previous history of pancreatic disease, evidence of active infection at presentation, presence of co-morbid malignancy, presence of obesity [BMI >35kg/msq] and not giving consent for study will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Development of pancreatic/extrapancreatic infection or sepsis within 30 days from onset. 2.Development of new onset organ failure [By Sequential organ failure assessment (SOFA) score] after randomization Timepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum levels of IL-6 at baseline and at 5 days after randomization in severe and moderately severe forms of pancreatitis. 2. Duration of hospitalization. Timepoint: 4 weeks | — |
Countries
India
Contacts
Public Contactanurag kumar tiwari
Institute of medical sciences, Banaras Hindu University
Outcome results
None listed